Acalabrutinib and Glucophage (Metformin) (Glucophage 500 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
The active acalabrutinib metabolite may inhibit MATE1 and increase metformin exposure.
Clinical significance and safety
With Acalabrutinib and Glucophage (Metformin), assess changes in metformin tolerability and the need for appropriate kidney-function or blood-glucose monitoring. The product information describes a transporter-based possibility, not a clinical finding of toxicity in every patient. It does not make the combination automatically contraindicated; the treatment team should decide whether any adjustment is needed.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.